Lamotrigine 2 MG Tablet for Oral Suspension — RxCUI 349010
RxNorm drug concept · Semantic clinical drug
RxCUI 349010
Semantic clinical drug · SCD
● Current RxNorm concept 16 FDA products
18 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI349010
Official nameLamotrigine 2 MG Tablet for Oral Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped16
Package NDCs mapped18
Reported Medicaid activity (SDUD)23,420 prescriptions · 38 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Lamotrigine: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- I completely understand the impatience — but the slow ramp-up is one of the most important safety steps with lamotrigine. Going too fast significantly raises your risk of a serious...
- Why does my doctor keep telling me to increase my dose so slowly? Can't we just get to the right dose faster?
- That's a fair question, and the honest answer is: with lamotrigine, we can't reliably tell in advance which rashes are harmless and which are dangerous. So the rule is — call your...
- What kind of rash should I worry about? I get skin reactions from all sorts of things.
🕸️ Concept Web — How Lamotrigine 2 MG Tablet for Oral Suspension Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Lamotrigine 2 MG Tablet for Oral Suspension
RxCUI 349010 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Lamotrigine
28439IN
-
Lamotrigine
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Lamictal
196502BN
-
Lamictal
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Lamotrigine Tablet for Oral Suspension
2697774SCDF -
Lamotrigine Oral Liquid Product
2697773SCDG -
Lamotrigine Oral Product
1162535SCDG -
Lamotrigine Tablet for Oral Suspension [Lamictal]
2697777SBDF -
Lamictal Oral Liquid Product
2697776SBDG -
Lamictal Oral Product
1174986SBDG -
Tablet for Oral Suspension
1861409DF -
Oral Liquid Product
1151137DFG - +1 more in this family
-
Lamotrigine Tablet for Oral Suspension
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Lamotrigine 2 MG
350517SCDC -
Lamotrigine 2 MG Tablet for Oral Suspension [Lamictal]
542426SBD -
Lamotrigine 2 MG [Lamictal]
542425SBDC
-
Lamotrigine 2 MG
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Lamotrigine 2 MG
SCDC · 350517 -
Lamotrigine Tablet for Oral Suspension
SCDF · 2697774 -
Lamotrigine Oral Liquid Product
SCDG · 2697773 -
Lamotrigine Oral Product
SCDG · 1162535
Brand-Name Concepts
-
Lamotrigine 2 MG Tablet for Oral Suspension [Lamictal]
SBD · 542426 -
Lamotrigine 2 MG [Lamictal]
SBDC · 542425 -
Lamotrigine Tablet for Oral Suspension [Lamictal]
SBDF · 2697777 -
Lamictal Oral Liquid Product
SBDG · 2697776 -
Lamictal Oral Product
SBDG · 1174986 -
Lamictal
BN · 196502
📦 FDA Products & Package NDCs
16 products · 18 package NDCs
18 package NDCs map to RxCUI 349010 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00173-0526-00 | 100 TABLET, FOR SUSPENSION in 1 BOTTLE (0173-0526-00) | LAMICTAL | GlaxoSmithKline LLC | 1998-09-04 |
| 00173-0527-00 | 100 TABLET, FOR SUSPENSION in 1 BOTTLE (0173-0527-00) | LAMICTAL | GlaxoSmithKline LLC | 1998-09-03 |
| 00173-0594-02 | 1 BLISTER PACK in 1 PACKAGE, COMBINATION (0173-0594-02) / 1... | LAMICTAL | GlaxoSmithKline LLC | 2003-09-29 |
| 00173-0633-02 | 100 TABLET in 1 BOTTLE (0173-0633-02) | LAMICTAL | GlaxoSmithKline LLC | 1996-08-15 |
| 00173-0633-10 | 35 TABLET in 1 DOSE PACK (0173-0633-10) | LAMICTAL | GlaxoSmithKline LLC | 1996-08-15 |
| 00173-0642-55 | 100 TABLET in 1 BOTTLE (0173-0642-55) | LAMICTAL | GlaxoSmithKline LLC | 1995-01-17 |
| 00173-0643-60 | 60 TABLET in 1 BOTTLE (0173-0643-60) | LAMICTAL | GlaxoSmithKline LLC | 1995-01-17 |
| 00173-0644-60 | 60 TABLET in 1 BOTTLE (0173-0644-60) | LAMICTAL | GlaxoSmithKline LLC | 1995-01-18 |
| 00173-0699-00 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (0173-0699-00) | LAMICTAL | GlaxoSmithKline LLC | 2000-10-12 |
| 00173-0699-02 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (0173-0699-02) | LAMICTAL | GlaxoSmithKline LLC | 2000-10-12 |
| 00173-0772-02 | 1 DOSE PACK in 1 CARTON (0173-0772-02) / 30 TABLET, ORALLY... | LAMICTAL ODT | GlaxoSmithKline LLC | 2009-06-05 |
| 00173-0774-02 | 1 DOSE PACK in 1 CARTON (0173-0774-02) / 30 TABLET, ORALLY... | LAMICTAL ODT | GlaxoSmithKline LLC | 2009-06-05 |
| 00173-0776-02 | 1 DOSE PACK in 1 CARTON (0173-0776-02) / 30 TABLET, ORALLY... | LAMICTAL ODT | GlaxoSmithKline LLC | 2009-06-05 |
| 00173-0777-02 | 1 DOSE PACK in 1 CARTON (0173-0777-02) / 30 TABLET, ORALLY... | LAMICTAL ODT | GlaxoSmithKline LLC | 2009-06-05 |
| 00173-0778-00 | 1 BLISTER PACK in 1 PACKAGE, COMBINATION (0173-0778-00) / 1... | LAMICTAL ODT | GlaxoSmithKline LLC | 2009-06-05 |
| 00173-0779-00 | 1 BLISTER PACK in 1 PACKAGE, COMBINATION (0173-0779-00) / 1... | LAMICTAL ODT | GlaxoSmithKline LLC | 2009-06-05 |
| 00173-0780-00 | 1 BLISTER PACK in 1 PACKAGE, COMBINATION (0173-0780-00) / 1... | LAMICTAL ODT | GlaxoSmithKline LLC | 2009-06-05 |
| 00173-0817-28 | 1 BLISTER PACK in 1 PACKAGE, COMBINATION (0173-0817-28) / 1... | LAMICTAL | GlaxoSmithKline LLC | 2003-09-29 |
Observed labelers:
GlaxoSmithKline LLC (18)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.